Osmind is the platform for breakthrough mental health research and treatment. Leading interventional clinicians rely on Osmind to safely administer, monitor, and analyze the use of TMS, ketamine, SPRAVATO®, psychedelic medicine, and other psychiatric medications for people living with moderate to severe mental health conditions. The core EHR technology is the first and only platform that solves specific challenges faced by these practices, capturing research-grade data while optimizing for mental health workflows and patient care journeys

Osmind works with scientists to analyze anonymized, aggregated real-world information to improve psychiatric clinical care and enable the discovery, development, and commercialization of next-generation therapeutics, diagnostics, and precision treatment approaches. Research from the Osmind platform is already helping to set new standards for mental health interventions, including recently the largest published real-world analysis of ketamine infusion therapy in collaboration with Stanford.

Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists. The company announced its $40M Series B round led by DFJ Growth in Spring 2022 and is also backed by General Catalyst, Future Ventures, Tiger Global, and Y Combinator.